Roche Launches Ventana HER2 Dual ISH CDx for the Identification of Breast and Gastric Cancer

 Shots:

• Roche’s Ventana HER2 Dual ISH DNA Probe Cocktail assay is used to detect HER2 biomarker in breast and gastric cancer patients receiving Herceptin (trastuzumab)
• The approval of Ventana HER2 Dual ISH assay supports Roche’s personalized healthcare sector by providing techniques to diagnose breast and gastric cancer
• The Ventana HER2 assay is fully automated on BenchMark IHC/ISH instruments providing results on the same day & can be read using light microscopy, launched in EU, the Middle East, Africa, Latin America & Asia Pacific with its expected regulatory submission to FDA 

Click here to read full press release/ article | Ref: Roche | Image: Ignition Dg